



Contact: Tularik Inc.
Traci McCarty
Investors/Media
Phone: 650-825-7182

Medarex, Inc.
Laura S. Choi
Investor Relations
Phone: 609-430-2880, x216

Jean Mantuano
Corporate Communications (media)
Phone: 609-430-2880, x221

Tularik and Medarex Announce Collaboration to Develop and Commercialize Human Therapeutic Antibodies

South San Francisco, Calif., and Princeton, NJ, January 9, 2002 — Tularik Inc. (Nasdaq: TLRK) and Medarex, Inc. (Nasdaq: MEDX) today announced a collaboration for the development of therapeutic antibodies for the treatment of a variety of common cancers. Medarex expects to use its UltiMab Human Antibody Development SystemSM to generate fully human antibodies based on three novel oncogenes discovered by Tularik. Oncogenes are genes that, when amplified or mutated, can lead to cancer.

Under the terms of the agreement, each of the two companies is expected to assume certain development responsibilities and costs. Financial terms were not disclosed.

"In recent years, Tularik's Genomics Division has developed a unique and very powerful technology platform for the high-throughput discovery of oncogenes. To date, we have discovered 18 oncogenes from common human tumors, many of which encode either small molecule or antibody targets," said David V. Goeddel, Ph.D., Tularik's CEO. "It has always been our strategy to focus on the development of small molecule drugs. However, we plan to opportunistically partner our oncogene discoveries in the area of antibody therapeutics."

Dr. Goeddel added, "We are excited to be working with Medarex. They have excellent technology and an outstanding track record in the development of human monoclonal antibodies. We see this type of collaborative effort as a model for the future development of therapeutic antibodies based on new oncogenes discovered by Tularik."

Donald L. Drakeman, President and CEO of Medarex, said, "We are particularly enthusiastic about the novel approach that Tularik has developed for selecting cancer targets. We believe the targets identified by Tularik have the potential to lead to the development of very effective therapeutic antibody drugs."

About Tularik

Tularik is engaged in the discovery and development of a broad range of novel and superior orally available drugs that act through the regulation of gene expression. Tularik programs address cancer, viral diseases, immune disorders, inflammation, obesity, lipid disorders and diabetes. Tularik currently has strategic partnerships with Japan Tobacco Inc. and Roche Bioscience. For more information, visit Tularik's Internet website at www.tularik.com.

Medarex, Inc. is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. Medarex has assembled a broad platform of patented technologies for antibody discovery and development, including the UltiMAb Human Antibody Development SystemSM for the creation of high-affinity, fully human antibodies; T-12 DevelopmentSM offering the potential to move from target to trial in approximately 12 months; and Trans-Phage TechnologySM combining high throughput screening with fully human antibody development. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody related capabilities, including pre-clinical and clinical development supported by cGMP manufacturing services. For more information about Medarex, visit its website at www.medarex.com.

For Tularik: This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Tularik to differ materially from those indicated by these forward-looking statements, including, among others, risks detailed from time to time in Tularik's SEC reports, including the report on Form 10-Q for the quarter ended September 30, 2001.

For Medarex: Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes"; "anticipates"; "intends"; "plans"; "expects"; "estimates"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product discovery and development as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2000 and subsequent Quarterly Reports on Form 10-Q. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex®, the Medarex logo, UltiMAb™, UltiMAb Human Antibody Development SystemSM, T-12 DevelopmentSM and Trans-Phage TechnologySM are trademarks and service marks of Medarex, Inc. All rights are reserved.